A new study from Tel Aviv University overturns prevailing scientific beliefs that King Solomon’s mines not only harmed the health of workers in the ancient copper industry but also pose risks to the health of modern residents living near the site.

A multicenter phase II trial has demonstrated that a combination of pyrotinib and fulvestrant offers significant antitumor activity and acceptable safety for hormone receptor-positive (HR+)/HER2-positive metastatic breast cancer patients who have developed resistance to trastuzumab. The study revealed a median progression-free survival (PFS) of 18.2 months and a disease control rate (DCR) of 97.5%, highlighting a novel therapeutic strategy for this challenging patient population.A multicenter phase II trial has demonstrated that a combination of pyrotinib and fulvestrant offers significant antitumor activity and acceptable safety for hormone receptor-positive (HR+)/HER2-positive metastatic breast cancer patients who have developed resistance to trastuzumab. The study revealed a median progression-free survival (PFS) of 18.2 months and a disease control rate (DCR) of 97.5%, highlighting a novel therapeutic strategy for this challenging patient population.